… Significant advances have been made in the development of targeted interventions for
hematologic malignancies. Progress has been made in defining the molecular pathogenesis of …

… in various hematological malignancies, inhibitors related to this … Efforts to exploit selective
inhibitors of the PI3K/Akt pathway that … for the PI3K/Akt pathway in hematologic malignancies. …

… Farnesyl transferase inhibitors (FTIs) are probably the best-studied class of Ras inhibitors
in hematologic malignancies. They block the enzyme farnesyl-transferase (FTase), which is …

… the context of hematological malignancies. Furthermore, we discuss the potential use of
JAKinibs for the treatment of diseases in which lymphocytes are the source of malignancies. In …

… JAK inhibitors to treat hematological malignancies originated … discovered in other hematological
malignancies such as acute … in hematological malignancies, where a JAK inhibitor may …

… , selective inhibitor of BCL2, have revealed responses across a variety of hematologic
malignancies. … and venetoclax in aggressive hematologic malignancies and provide a rationale for …

… this phenomenon occurs in hematological malignancies. This review presents evidence that
targeting the glycolytic pathway at different levels in hematological malignancies can inhibit …

… the development of hematologic malignancies such as … hematologic compartment homeostasis
(Figure 2), which may account for the observed association of hematologic malignancies …

… practice in the hematologic malignancies is the proteasome inhibitor bortezomib (Velcade, …
inhibits proteasomes found in all cell types, it is targeted in the sense that malignant plasma …

… (PEX) domain inhibitors as well as … inhibitors had been reported against hematologic
malignant cells. Several substrate based non-selective to non-substrate based relatively selective …